Bin Peng

Before joining EpimAb, Bin Peng, MD, PhD, was the Global Head of Oncology Translational Medicine, China at Novartis. Prior to this, he was appointed as the Senior Director of Clinical Pharmacology at GlaxoSmithKline, U.S. Dr. Peng served as a Senior Clinical Pharmacologist at Novartis in Switzerland where he was involved in the entire clinical development of Gleevec® from 1998 with the Phase I study in humans till its worldwide registration in 2001. Dr. Peng received his MD degree from Sun Yet-Sen University of Medical Sciences in Guangzhou, China. He then earned a PhD in Cancer Clinical Pharmacology at the Cancer Research Unit, University of Newcastle Upon Tyne, U.K and completed a postdoctoral fellowship at Manchester University, U.K. He is also an adjunct professor at Institute of Clinical Research of Beijing University and has authored more than 70 papers and abstracts on clinical pharmacology and clinical research for early cancer/hematology drugs.